Provided by Tiger Trade Technology Pte. Ltd.

C4 Therapeutics, Inc.

2.78
+0.01000.36%
Volume:4.40M
Turnover:12.15M
Market Cap:271.27M
PE:-1.66
High:3.00
Open:2.93
Low:2.61
Close:2.77
52wk High:3.65
52wk Low:1.09
Shares:97.58M
Float Shares:72.05M
Volume Ratio:1.32
T/O Rate:6.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6711
EPS(LYR):-1.5181
ROE:-59.98%
ROA:-23.20%
PB:1.76
PE(LYR):-1.83

Loading ...

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

GlobeNewswire
·
Jan 14

C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch

TIPRANKS
·
Jan 13

C4 Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 18, 2025

U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources

Reuters
·
Dec 17, 2025

C4 Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating

THOMSON REUTERS
·
Dec 03, 2025

C4 Therapeutics Initiated at Buy by TD Cowen

Dow Jones
·
Dec 02, 2025

TD Cowen Initiates C4 Therapeutics at Buy

MT Newswires Live
·
Dec 02, 2025

C4 Therapeutics to Participate in Evercore Healthcare Conference

Reuters
·
Nov 25, 2025

C4 Therapeutics Files $400 Million Mixed Shelf

MT Newswires Live
·
Nov 22, 2025

C4 Therapeutics files $400M mixed securities shelf

TIPRANKS
·
Nov 22, 2025

C4 Therapeutics Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing

THOMSON REUTERS
·
Nov 22, 2025

C4 Therapeutics Q3 EPS USD -0.44

Reuters
·
Nov 20, 2025

2 Days to Go: Crypto Content Creator Campus Launches Kaito-Powered Mindshare Leaderboard to Celebrate the Voices Shaping Web3 Conversations

prnewswire
·
Nov 12, 2025

OKX Web3 Joins Founding Sponsor Bybit to Power CCCC Lisbon 2025

prnewswire
·
Nov 11, 2025

C4 Therapeutics Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 07, 2025

C4 Therapeutics Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline

Reuters
·
Nov 06, 2025

C4 Therapeutics Q3 EPS USD -0.44

Reuters
·
Nov 06, 2025

C4 Therapeutics Q3 EPS $(0.44) Misses $(0.40) Estimate, Sales $11.230M Beat $6.280M Estimate

Benzinga
·
Nov 06, 2025

C4 Therapeutics Raises $125 Million and Reports Positive Phase 1 Cemsidomide Data

Reuters
·
Nov 06, 2025

C4 Therapeutics: Expects Current Cash, Cash Equivalents & Marketable Securities Will Enable Co to Fund Its Operating Plan to End of 2028

THOMSON REUTERS
·
Nov 06, 2025